- No products in the cart.
Compounding for Crohn’s Disease & Ulcerative Colitis
What is Crohn’s Disease?
Crohn’s disease causes inflammation of the digestive tract (mouth, esophagus, stomach, small intestine, large intestine, anus) and symptoms caused by that may be abdominal pain, severe diarrhea and fatigue. Different areas of the GI tract may also be affected in different people.
In some people with Crohn’s disease, it only affects the colon. In others it may also affect the small intestine only.
Crohn’s Disease and Ulcerative Colitis (UC) fall under a condition called Inflammatory Bowel Disease (IBD) and are characterized by chronic inflammation in the gastrointestinal (GI) tract.
An estimated 30% of patients with inflammatory bowel disease (IBD) don’t respond well to current therapy or may relapse over time. New treatment options are necessary and Low Dose Naltrexone (LDN) may be able to help these patients.
The disease can often be debilitating. A great compounding pharmacy like ICP Folsom may be another resource for you to consider using in your quest. Contact ICP Folsom today by calling: 866.470.9197
What is Crohn’s Disease?
The most common areas of the body impacted by Crohn’s disease are the end of small intestine plus the colon. The symptoms of Crohn’s disease can flare up suddenly and without any warning and there are also times when patients do not have any symptoms.
According to the Mayo Clinic, flare ups of the disease can include any of the below:
- Diarrhea
- Fever
- Fatigue
- Abdominal pain and cramping
- Blood in the stool
- Mouth sores
- Reduced appetite and weight loss
- Pain or drainage near or around the anus due to inflammation from a tunnel into the skin (fistula)
Crohn’s 101 – Overview This introductory video provides information on potential causes, symptoms, treatment and overall management of Crohn’s disease.
Source: Crohns Colitis Foundation
Low Dose Naltrexone (LDN)
Read about the mechanism in which low dose naltrexone LDN works to reduce inflammation.
Abstract Low-dose naltrexone (LDN) has been demonstrated to reduce symptom severity in conditions such as fibromyalgia, Crohn’s disease, multiple sclerosis, and complex regional pain syndrome. We review the evidence that LDN may operate as a novel anti-inflammatory agent in the central nervous system, via action on microglial cells. These effects may be unique to low dosages of naltrexone and appear to be entirely independent from naltrexone’s better-known activity on opioid receptors. As a daily oral therapy, LDN is inexpensive and well-tolerated. Despite initial promise of efficacy, the use of LDN for chronic disorders is still highly experimental. Published trials have low sample sizes, and few replications have been performed. We cover the typical usage of LDN in clinical trials, caveats to using the medication, and recommendations for future research and clinical work. LDN may represent one of the first glial cell modulators to be used for the management of chronic pain disorders.
What is Low Dose Naltrexone (LDN)?
Naltrexone belongs to a class of drugs known as opioid antagonists. Naltrexone blocks opiate drugs from binding to the opioid receptors, which can result in increased endorphin and enkephalin release. Therefore, this results in reduced: 1. signaling and release of inflammatory substances, 2. nerve cell inflammation and 3. autoimmune mediators.